Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CORI
CUSIPN/A
Phone650-298-8012
Debt
Debt-to-Equity Ratio1.89
Current Ratio8.11
Quick Ratio7.95
Price-To-Earnings
Trailing P/E Ratio-5.43
Forward P/E Ratio-5.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.86 million
Price / Sales10.12
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book19.78
Profitability
EPS (Most Recent Fiscal Year)($1.64)
Net Income$-47,790,000.00
Net Margins-156.05%
Return on Equity-273.01%
Return on Assets-61.11%
Miscellaneous
Employees213
Outstanding Shares36,240,000
Corium International (NASDAQ:CORI) Frequently Asked Questions
What is Corium International's stock symbol?
Corium International trades on the NASDAQ under the ticker symbol "CORI."
How were Corium International's earnings last quarter?
Corium International Inc (NASDAQ:CORI) posted its earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04. The biopharmaceutical company earned $10.06 million during the quarter, compared to analysts' expectations of $7.07 million. Corium International had a negative net margin of 156.05% and a negative return on equity of 273.01%. View Corium International's Earnings History.
What price target have analysts set for CORI?
5 Wall Street analysts have issued 1 year target prices for Corium International's stock. Their predictions range from $10.00 to $14.00. On average, they anticipate Corium International's share price to reach $13.00 in the next year. View Analyst Ratings for Corium International.
What are Wall Street analysts saying about Corium International stock?
Here are some recent quotes from research analysts about Corium International stock:
- 1. Cantor Fitzgerald analysts commented, "Our CORI , 2019E — — — — REV 1Q 2Q 3Q 4Q 2017A 7.0A 7.3A 8.1A 9.4A 2018E 9.3A 10.1A 8.0E 8.0E 2019E — — — —." (5/18/2018)
- 2. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (5/17/2018)
Who are some of Corium International's key competitors?
Some companies that are related to Corium International include Amneal Pharmaceuticals (AMRX), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Athenex (ATNX), Alder Biopharmaceuticals (ALDR), Arrowhead Pharmaceuticals (ARWR), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Wave Life Sciences (WVE), Reata Pharmaceuticals (RETA), Esperion Therapeutics (ESPR) and Flexion Therapeutics (FLXN).
Who are Corium International's key executives?
Corium International's management team includes the folowing people:
- Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
- Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
- Dr. Parminder Singh, CTO & VP of R&D (Age 54)
- Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
- Ms. Christina Dickerson, VP of Corp. Devel.
Has Corium International been receiving favorable news coverage?
Media stories about CORI stock have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Corium International earned a news sentiment score of 0.10 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.33 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Corium International's major shareholders?
Corium International's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (5.70%), BlackRock Inc. (5.21%), Tamarack Advisers LP (3.06%), Northern Trust Corp (0.67%), Needham Investment Management LLC (0.62%) and Candriam Luxembourg S.C.A. (0.54%). Company insiders that own Corium International stock include Healthcare Master Fun Broadfin, Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Perceptive Advisors Llc and Timothy D Sweemer. View Institutional Ownership Trends for Corium International.
Which major investors are selling Corium International stock?
CORI stock was sold by a variety of institutional investors in the last quarter, including Needham Investment Management LLC, Northern Trust Corp, Schwab Charles Investment Management Inc. and California State Teachers Retirement System. Company insiders that have sold Corium International company stock in the last year include Healthcare Master Fun Broadfin, Joseph J Sarret, Parminder Singh and Timothy D Sweemer. View Insider Buying and Selling for Corium International.
Which major investors are buying Corium International stock?
CORI stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Candriam Luxembourg S.C.A., Tamarack Advisers LP, JPMorgan Chase & Co., Citadel Advisors LLC, Iguana Healthcare Management LLC and DekaBank Deutsche Girozentrale. Company insiders that have bought Corium International stock in the last two years include Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Corium International.
How do I buy shares of Corium International?
Shares of CORI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corium International's stock price today?
One share of CORI stock can currently be purchased for approximately $8.90.
How big of a company is Corium International?
Corium International has a market capitalization of $320.02 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Corium International employs 213 workers across the globe.
How can I contact Corium International?
Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8012 or via email at [email protected]
MarketBeat Community Rating for Corium International (CORI)
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days.
